Akums Drugs and Pharmaceuticals Ltd
Akums Drugs and Pharma: Board approves FY26 results, Rs. 3.00 dividend per share
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 14 May 2026, 01:51 PM IST · BSE ID: e0daa136-3e8b-459b-b187-c2857f1ab4c8
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its full-year financial results for FY26 and recommended a total dividend of Rs. 3.00 per share.
🤖 AI Summary
- Akums Drugs and Pharmaceuticals Board approved Un-audited Q4 FY26 and Audited FY26 Standalone & Consolidated Financial Results.
- Recommended a Final Dividend of Rs. 1.00/- per equity share and a Special Dividend of Rs. 2.00/- per equity share.
- Fixed Friday, July 03, 2026, as the Record Date for the recommended final and special dividend payments.
- Re-appointed M/s. Balwinder & Associates as Cost Auditors for FY27 for Rs. 3,00,000/- remuneration.
- Appointed Mahajan & Aibara LLP as Internal Auditors for FY27 and announced changes in Senior Management Personnel.
🏢 How This Affects the Company
The dividend recommendation will lead to a cash outflow from the company's reserves upon shareholder approval and payment.
Re-appointment of cost auditors and appointment of internal auditors ensures continued financial oversight and compliance. Changes in senior HR management indicate a shift in leadership within that function.
The emphasis of matter regarding a search and seizure operation by the Income Tax Department during FY25 presents an unquantified financial and reputational risk, as the impact is not yet ascertainable.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must hold shares by the record date of July 03, 2026, to be eligible for the recommended dividend, subject to AGM approval.
👤
Who Is Affected
All shareholders on record as of July 03, 2026, will be eligible to receive a total dividend of Rs. 3.00 per equity share, comprising a Rs. 1.00 final dividend and a Rs. 2.00 special dividend.
🔍
Management Signal
The Board's recommendation of both a final and special dividend signals a policy of returning capital to shareholders, alongside regular governance decisions for auditing and management.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Annual General Meeting (July 10, 2026) — shareholder approval of dividend and auditor appointments.
Dividend payment (within 30 days of AGM approval) — check for actual disbursement.
Income Tax proceedings updates — look for filings on resolution or quantification of the matter.
MEDIUM RISK
The unquantified financial impact of the ongoing Income Tax search and seizure proceedings presents a specific, material risk.
💡 Investor Takeaway
Akums Drugs and Pharmaceuticals' Board approved FY26 financial results and recommended a total dividend of Rs. 3.00 per equity share. The audit report noted an unquantified impact from an ongoing Income Tax search and seizure operation from FY25, with a show cause notice received after March 31, 2026.
⚖️ Strengths & Concerns
⚠️ Concerns
- An emphasis of matter from the auditor highlights ongoing Income Tax Department search and seizure proceedings from FY25, with an unquantified financial impact for FY26.
- The company received a show cause notice under section 158BC of the Tax Act subsequent to the year ended March 31, 2026, creating an unresolved tax liability uncertainty.
📅 Company Track Record
No previous filings found for this company provide sufficient historical financial data to establish trends or specific comparable events.
Based on publicly available historical data. For context only.